Heart International最新文献_第5页

A Comprehensive Review of Mechanical Circulatory Support Devices. 机械循环支持设备的全面回顾。

IF 1.9

Heart International Pub Date : 2022-03-04 eCollection Date: 2022-01-01 DOI: 10.17925/HI.2022.16.1.37

Varunsiri Atti, Mahesh Anantha Narayanan, Brijesh Patel, Sudarshan Balla, Aleem Siddique, Scott Lundgren, Poonam Velagapudi

{"title":"A Comprehensive Review of Mechanical Circulatory Support Devices.","authors":"Varunsiri Atti, Mahesh Anantha Narayanan, Brijesh Patel, Sudarshan Balla, Aleem Siddique, Scott Lundgren, Poonam Velagapudi","doi":"10.17925/HI.2022.16.1.37","DOIUrl":"10.17925/HI.2022.16.1.37","url":null,"abstract":"Treatment strategies to combat cardiogenic shock (CS) have remained stagnant over the past decade. Mortality rates among patients who suffer CS after acute myocardial infarction (AMI) remain high at 50%. Mechanical circulatory support (MCS) devices have evolved as novel treatment strategies to restore systemic perfusion to allow cardiac recovery in the short term, or as durable support devices in refractory heart failure in the long term. Haemodynamic parameters derived from right heart catheterization assist in the selection of an appropriate MCS device and escalation of mechanical support where needed. Evidence favouring the use of one MCS device over another is scant. An intra-aortic balloon pump is the most commonly used short-term MCS device, despite providing only modest haemodynamic support. Impella CP® has been increasingly used for CS in recent times and remains an important focus of research for patients with AMI-CS. Among durable devices, Heartmate® 3 is the most widely used in the USA. Adequately powered randomized controlled trials are needed to compare these MCS devices and to guide the operator for their use in CS. This article provides a brief overview of the types of currently available MCS devices and the indications for their use.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 1","pages":"37-48"},"PeriodicalIF":1.9,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524665/pdf/heart-int-16-37.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden. 评价Omega-3脂肪酸对冠状动脉斑块特征和负荷影响的多模态影像学试验。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/hi.2022.16.1.2

V. Manubolu, M. Budoff, S. Lakshmanan

{"title":"Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden.","authors":"V. Manubolu, M. Budoff, S. Lakshmanan","doi":"10.17925/hi.2022.16.1.2","DOIUrl":"https://doi.org/10.17925/hi.2022.16.1.2","url":null,"abstract":"Treatment of established risk factors, especially low-density lipoprotein (LDL) cholesterol, is the cornerstone of preventing atherosclerotic coronary artery disease. Despite reducing LDL cholesterol, there remains a significant risk of cardiovascular disease. Inflammatory and metabolic pathways contribute to recurrence of cardiovascular events, and are often missed in clinical practice. Eicosapentaenoic acid (EPA) may play a crucial role in reducing residual risk of cardiovascular disease. In this review we discuss the clinical applications of omega-3 fatty acids (OM3FAs), their mechanism of action, the difference between pure EPA and docosahexaenoic acid components, and the latest cardiovascular outcome trials and imaging trials evaluating coronary plaque. PubMed and EMBASE were searched to include all the remarkable clinical trials investigating OM3FAs and cardiovascular disease. Beyond statins, additional medications are required to reduce the risk of cardiovascular disease. EPA has shown cardiovascular benefit in addition to statins in large outcome trials. Additionally, multiple serial-imaging studies have demonstrated benefits on plaque progression and stabilization. Due to its pleotropic properties, icosapent ethyl outperforms other OM3FAs in decreasing cardiovascular disease risk in both patients with and without high triglycerides, and is currently recommended as an adjunct to statins. To further strengthen the current evidence, additional research is required to elucidate the inconsistencies between the effects of pure EPA and EPA plus docosahexaenoic acid.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 1 1","pages":"2-11"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Natriuretic Peptide-guided Therapy for Heart Failure. 利钠肽引导心力衰竭治疗。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.112

Yu Horiuchi, Humberto Villacorta, Alan S Maisel

{"title":"Natriuretic Peptide-guided Therapy for Heart Failure.","authors":"Yu Horiuchi, Humberto Villacorta, Alan S Maisel","doi":"10.17925/HI.2022.16.2.112","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.112","url":null,"abstract":"Heart failure (HF) is a complex syndrome with high mortality and hospitalization rates. Conventional care in patients with HF is usually based on clinical history and physical examination. Natriuretic peptides (NPs), B-type NP (BNP) and N-terminal proBNP, are the gold-standard biomarkers in HF. They are recommended for diagnosing HF, when the physician is uncertain of the diagnosis, and for estimating the prognosis. NPs also guide therapy in HF, as serial NP measurements inform medication adjustments to achieve targets independently of symptoms. In this regard, the data are conflicting. In patients with HF and reduced left ventricular ejection fraction (HFrEF) there is a suggestion that NP-guided therapy is helpful. The studies STARS-BNP and PROTECT demonstrated a reduction in cardiac events with NP-guided therapy. Additionally, mortality in patients aged <75 years reduced in the BATTLESCARRED and TIME-CHF studies, and in a meta-analysis. On the contrary, no differences were observed in the studies PRIMA and GUIDE-IT. In HF with preserved ejection fraction (HFpEF) and in the acute setting, no differences were detected with NP-guided therapy compared with conventional care. In patients at risk of developing HF, NP can be useful to guide therapy and prevent HF. In summary, NP-guided therapy seems to be useful in patients with HFrEF, especially in those aged <75 years, but has no use in HFpEF or in acute HF.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"112-116"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872778/pdf/heart-int-16-112.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9213133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention. 降低经皮左心室辅助装置支持的高危经皮冠状动脉介入治疗血管和出血风险的策略。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.105

George W Vetrovec, Amir Kaki, Jason Wollmuth, Thom G Dahle

{"title":"Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention.","authors":"George W Vetrovec, Amir Kaki, Jason Wollmuth, Thom G Dahle","doi":"10.17925/HI.2022.16.2.105","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.105","url":null,"abstract":"In patients at high risk for haemodynamic instability during percutaneous coronary intervention (PCI), practitioners are increasingly opting for prophylactic mechanical circulatory support, such as the Impella® heart pump (Abiomed, Danvers, MA, USA). Though Impella-supported high-risk PCI (HRPCI) ensures haemodynamic stability during the PCI procedure, access-related complication rates have varied significantly in published studies. Reported variability in complication rates relates to many factors, including anticoagulation practices, access and closure strategy, post-procedure care and variations in event definitions. This article aims to outline optimal strategies to minimize vascular and bleeding complications during Impella-supported HRPCI based on previously identified clinical, procedural and postprocedural risk factors. Practices to reduce complications include femoral skills training, standardized protocols to optimize access, closure, anticoagulation management and post-procedural care, as well as the application of techniques and technological advances. Protocols integrating these strategies to mitigate access-related bleeding and vascular complications for Impella-supported procedures can markedly limit vascular access risk as a barrier to appropriate large-bore mechanical circulatory support use in HRPCI.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"105-111"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872781/pdf/heart-int-16-105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9213131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Globe Pulsed Field System for High-definition Mapping and Ablation for Atrial Fibrillation. 用于房颤高清晰定位和消融的全球脉冲场系统。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.85

Paula Sanchez-Somonte, Atul Verma

{"title":"Globe Pulsed Field System for High-definition Mapping and Ablation for Atrial Fibrillation.","authors":"Paula Sanchez-Somonte, Atul Verma","doi":"10.17925/HI.2022.16.2.85","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.85","url":null,"abstract":"Pulmonary vein isolation (PVI) is the cornerstone of atrial fibrillation ablation. Radiofrequency ablation has been the most common source of energy used to achieve PVI until now. In recent years, cryoballoon ablation has gained popularity due to its ability to perform PVI in a 'single-shot' fashion. In both cases (radiofrequency and cryoablation), the main limitation is their inability to achieve durable lesions without causing collateral damage to adjacent structures. In contrast, pulsed electric field (PEF) ablation is a non-thermal energy source that causes cell apoptosis by applying an electric current to the tissue. Lesions created by a field of energy seem to be more contiguous than traditional ablation, and the risk of damage to adjacent tissues is largely avoided due to the properties of the tissues and electrical fields. In recent years, new catheters capable of delivering PEF have been developed and are now undergoing clinical testing. In this article, we describe a complete solution for PVI: a single multielectrode catheter with 3D mapping capabilities that can deliver PEF in a single-shot PVI fashion with targeting beyond the pulmonary veins.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"85-90"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872786/pdf/heart-int-16-85.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10716070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of the Past, Present and Future of Cancer-associated Thrombosis Management. 癌症相关血栓管理的过去、现在和未来综述。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.117

Randy K Ramcharitar, Louise Man, Minhaj S Khaja, Merry Ellen Barnett, Aditya Sharma

{"title":"A Review of the Past, Present and Future of Cancer-associated Thrombosis Management.","authors":"Randy K Ramcharitar, Louise Man, Minhaj S Khaja, Merry Ellen Barnett, Aditya Sharma","doi":"10.17925/HI.2022.16.2.117","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.117","url":null,"abstract":"Venous thromboembolism (VTE) can have a significant impact on the management, quality of life and mortality of patients with cancer. VTE occurs in 5-20% of patients with cancer, and malignancy is associated with up to 25% of all VTE. It is the second leading cause of death in ambulatory patients with cancer who are receiving chemotherapy. Increased rates of cancer-associated thrombosis are attributed to improved patient survival, increased awareness, surgery, antineoplastic treatments and the use of central venous access devices. Many factors influence cancer-associated thrombosis risk and are broadly categorized into patient-related, cancer-related and treatment-related risks. Direct-acting oral anticoagulants have shown themselves to be at least as effective in preventing recurrent VTE in patients with cancer with symptomatic and incidental VTE. This has led to a change in treatment paradigms so that direct-acting oral anticoagulants are now considered first-line agents in appropriately selected patients. In this article, we review the prior and recent landmark studies that have directed the treatment of cancer-associated thrombosis, and discuss specific factors that affect management as well as future treatment considerations.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"117-123"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870322/pdf/heart-int-16-117.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10599933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy. 马伐卡坦:治疗症状性肥厚性梗阻性心肌病的一流口服心肌蛋白调节剂。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.91

Klevin Roger L Reyes, Gizem Bilgili, Florian Rader

{"title":"Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.","authors":"Klevin Roger L Reyes, Gizem Bilgili, Florian Rader","doi":"10.17925/HI.2022.16.2.91","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.91","url":null,"abstract":"Hypertrophic cardiomyopathy is the most common monogenic cardiovascular disease that is caused by sarcomeric protein gene mutations. A hallmark of the most common form of the disease is outflow obstruction secondary to systolic narrowing of the left ventricular outflow tract from septal hypertrophy, mitral valve abnormalities and, most importantly, hyperdynamic contractility. Recent mechanistic studies have identified excessive myosin adenosine triphosphatase activation and actin-myosin cross-bridging as major underlying causes. These studies have led to the development of mavacamten, a first-in-class myosin adenosine triphosphatase inhibitor and the first specific therapy for hypertrophic obstructive cardiomyopathy. Preclinical and subsequent pivotal clinical studies have demonstrated the efficacy and safety of mavacamten. A remarkable improvement among treated patients in peak oxygen consumption, functional capacity, symptom relief and post-exercise left ventricular outflow tract gradient, along with dramatic reductions in heart failure biomarkers, suggests that this new medication will be transformative for the symptom management of hypertrophic obstructive cardiomyopathy. There is also hope and early evidence that mavacamten may delay or obviate the need for invasive septal reduction therapies. In this article, we review the current evidence for the efficacy and safety of mavacamten and highlight important considerations for its clinical use.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"91-98"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872784/pdf/heart-int-16-91.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10716072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Side Branch is the Main Determinant Factor of Bifurcation Lesion Complexity: Critical Review with a Proposal Based on Single-centre Experience. 侧支是分叉病变复杂性的主要决定因素：基于单中心经验的批判性回顾与建议

IF 1.9

Heart International Pub Date : 2021-12-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.67

Imad Sheiban, Filippo Figini, Valeria Gasparetto, Fabrizio D'Ascenzo, Claudio Moretti, Filippo Leonardo

引用次数: 0

A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better? 超薄支架药物洗脱支架的述评:越薄越好?

IF 0.2

Heart International Pub Date : 2021-12-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.84

Maik J Grundeken, Marcel Am Beijk

引用次数: 4

Latest Advances in Transcatheter Mitral Valve Replacement. 经导管二尖瓣置换术的最新进展。

IF 0.2

Heart International Pub Date : 2021-12-20 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.79

Tomoya T Hinohara, Michael J Reardon, Sachin S Goel

引用次数: 2